StockWatch
·
Q2 FY-2027 RESULTS · FERMENTA

Fermenta Biotech Q2 FY27: consolidated PAT down 48% YoY, NPM compresses to 6.9%

PAT -47.66% YoY · revenue +1.88% · margins compressing

Q2 FY27 resultsFERMENTAFermenta Biotech Ltd05 Nov 2026 · 3 min read
Revenue

₹132.67 Cr

+1.88% YoY

PAT (consolidated)

₹9.44 Cr

-47.66% YoY

Net margin

6.95%

-6.3pp YoY

EPS

₹3.4

Fermenta Biotech's consolidated (primary basis) PAT fell 47.7% YoY to ₹9.44 Cr even as consolidated revenue was nearly flat, up just 1.9% YoY to ₹132.67 Cr from ₹130.22 Cr — profit growth trailed revenue growth by a wide margin, and NPM compressed to 6.95% from 13.29% a year ago (also down from 7.55% in Q1 FY27). Standalone (secondary basis) tells a materially milder story: standalone PAT fell only 5.2% YoY to ₹13.95 Cr on 9.2% YoY revenue growth to ₹116.94 Cr, a >40-percentage-point gap in PAT growth versus the consolidated print. Readers comparing the two numbers should not assume either is wrong — the divergence is explained below.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹132.67 Cr+8.9%+1.9%
Expenses₹121.51 Cr+9%+8.9%
PAT₹9.44 Cr-0.99%-47.66%
Net margin6.95%-0.6pp-6.3pp
EPS₹3.40%-47.5%

The margin squeeze sits mainly below the core operating line: the core bulk drugs/chemicals segment, which is the real operating engine, saw its segment profit fall 28.5% YoY to ₹18.98 Cr (from ₹26.55 Cr) even as segment revenue rose, implying cost pressure within the core business itself. On top of that, the company's three overseas units (UK, Germany, US) swung to a combined ₹2.71 Cr net loss this quarter per the statutory auditor's review note — a drag that doesn't show up in the standalone numbers — while the Environment segment (housed in subsidiary FESPL) added a further ₹1.76 Cr segment loss, narrower than Q1's ₹2.71 Cr loss but still a drag. Finance costs rose to ₹3.73 Cr from ₹2.58 Cr a year ago, adding to the pressure. Operating margin (profit before tax and finance cost over revenue from operations) eased to roughly 13.6% from about 20.5% YoY.

₹
397.91444.52491.13537.73584.34424.908-0308-2509-1710-1211-0411-05Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹424.9, down 25% over the past month of trading.

₹ Cr
08.0616.1324.1921.6Q1 FY26rev ₹136 Cr18.03Q2 FY26rev ₹130 Cr12.02Q3 FY26rev ₹137 Cr18.6Q4 FY26rev ₹122 Cr9.53Q1 FY27rev ₹122 Cr9.44Q2 FY27rev ₹133 Cr
Quarterly consolidated PAT, ₹ Crore
Beyond the headline

What the summary numbers don't show

No exceptional items in the current or year-ago quarter (unlike FY26 annual, which had a ₹6.97 Cr net exceptional gain), so the YoY decline is on a clean, like-for-like basis.

There is no formal management guidance on record for this quarter — neither in our database nor in the filing itself — and no management press release was available to extract commentary from, so there is nothing from the company to grade this print against. A web search for analyst/consensus estimates ahead of this result found none specific to Fermenta Biotech's Q2 FY27 (results were approved and released the same day as the search, and the stock has thin formal sell-side coverage), so vsStreet is unknown rather than assumed. Sequentially, revenue grew 8.9% QoQ to ₹132.67 Cr but PAT was essentially flat, down 1.0% QoQ to ₹9.44 Cr from ₹9.53 Cr, consistent with a business where topline recovery hasn't yet translated into profit recovery. Separately, during the quarter promoter-linked holder Preeti Thakkar sold a 3.96% stake (Sep 30, 2026) and the company licensed Vitamin B12 fortification technology from VIT (Sep 8, 2026) — a core-segment initiative with no quantifiable revenue impact yet disclosed — while subsidiary FESPL raised ₹21.53 lakh via a private placement and set up an ESOP pool, developments relevant to the Environment segment's capital base rather than this quarter's P&L.

  • W1

    Overseas subsidiaries (UK/Germany/US) swung to a combined ₹2.71 Cr net loss this quarter — watch for a return to breakeven in Q3 FY27.

  • W2

    Core bulk drugs/chemicals segment profit fell 28.5% YoY to ₹18.98 Cr — watch whether this stabilizes given no formal management guidance is on record.

  • W3

    Environment segment (FESPL) loss narrowed to ₹1.76 Cr from ₹2.71 Cr in Q1 FY27 — watch the pace of further narrowing following this quarter's capital raise and ESOP grant.

Informational and educational content only. Not investment advice.